Jefferies Financial Group Inc. Invests $6.94 Million in DaVita Inc. $DVA

Jefferies Financial Group Inc. bought a new position in DaVita Inc. (NYSE:DVA) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 61,051 shares of the company’s stock, valued at approximately $6,936,000. Jefferies Financial Group Inc. owned approximately 0.09% of DaVita at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in DVA. Arrowstreet Capital Limited Partnership grew its position in DaVita by 109.7% during the third quarter. Arrowstreet Capital Limited Partnership now owns 553,809 shares of the company’s stock valued at $73,585,000 after purchasing an additional 289,725 shares in the last quarter. Man Group plc grew its position in DaVita by 1,608.6% in the second quarter. Man Group plc now owns 285,809 shares of the company’s stock worth $40,713,000 after acquiring an additional 269,081 shares in the last quarter. Neuberger Berman Group LLC grew its position in DaVita by 138.5% in the third quarter. Neuberger Berman Group LLC now owns 463,250 shares of the company’s stock worth $61,502,000 after acquiring an additional 269,015 shares in the last quarter. Voloridge Investment Management LLC grew its position in DaVita by 2,905.7% in the third quarter. Voloridge Investment Management LLC now owns 228,221 shares of the company’s stock worth $30,324,000 after acquiring an additional 220,628 shares in the last quarter. Finally, Todd Asset Management LLC bought a new stake in DaVita in the third quarter worth approximately $21,842,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on DVA shares. TD Cowen boosted their target price on shares of DaVita from $144.00 to $201.00 and gave the stock a “hold” rating in a research report on Monday, May 11th. Truist Financial boosted their target price on shares of DaVita from $158.00 to $205.00 and gave the stock a “hold” rating in a research report on Friday, May 8th. Deutsche Bank Aktiengesellschaft raised shares of DaVita from a “hold” rating to a “buy” rating and boosted their target price for the stock from $126.00 to $220.00 in a research report on Wednesday, May 6th. Wall Street Zen raised shares of DaVita from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Finally, Zacks Research upgraded shares of DaVita from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $199.17.

DaVita Stock Performance

Shares of DVA stock opened at $198.39 on Tuesday. DaVita Inc. has a 52-week low of $101.00 and a 52-week high of $202.69. The stock has a market cap of $12.74 billion, a price-to-earnings ratio of 18.40, a P/E/G ratio of 0.65 and a beta of 0.84. The firm has a fifty day moving average of $163.84 and a 200-day moving average of $138.82.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, topping the consensus estimate of $2.33 by $0.54. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The business had revenue of $3.42 billion for the quarter, compared to analyst estimates of $3.36 billion. During the same quarter in the prior year, the firm earned $2.00 EPS. The firm’s quarterly revenue was up 6.0% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, sell-side analysts predict that DaVita Inc. will post 15.07 earnings per share for the current year.

Insider Buying and Selling

In other DaVita news, CFO Joel Ackerman sold 51,471 shares of the company’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the transaction, the chief financial officer directly owned 132,434 shares in the company, valued at approximately $25,440,571.40. This represents a 27.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.50% of the stock is currently owned by corporate insiders.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.